We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

By LabMedica International staff writers
Posted on 16 Jul 2024

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. More...

This escalation in resistance raises the concern of some infections soon becoming untreatable. A major challenge for healthcare providers is quickly distinguishing between organisms that respond to standard first-line drugs and those that are resistant. Traditional testing methods, which involve culturing bacteria, testing them against various antimicrobial agents, and either manual or machine analysis, can take several days. This delay often leads to the administration of ineffective drugs, which can cause more severe health issues and potentially contribute to the development of further drug resistance. Researchers have now demonstrated that artificial intelligence (AI) can significantly cut down the time needed to accurately diagnose drug-resistant infections. They have developed an algorithm capable of correctly identifying drug-resistant bacteria from microscopy images alone.

In research published in Nature Communications, the team of researchers from the University of Cambridge (Cambridge, UK) created a machine-learning tool that can identify from microscopy images the bacteria Salmonella typhimurium, which is resistant to the first-line antibiotic ciprofloxacin, without needing to directly expose the bacteria to the drug. S. Typhimurium is known to cause gastrointestinal and typhoid-like illnesses, with symptoms such as fever, fatigue, headache, nausea, abdominal pain, and constipation or diarrhea, which can be life-threatening in severe cases. Although treatable with antibiotics, the bacteria are increasingly developing resistance to several drugs, complicating treatment efforts.

The research team utilized high-resolution microscopy to study S. Typhimurium isolates subjected to varying concentrations of ciprofloxacin, identifying the five most crucial imaging features to differentiate between resistant and susceptible strains. They trained a machine-learning algorithm to recognize these features from the imaging data of 16 samples. Impressively, the algorithm could accurately determine whether the bacteria were susceptible or resistant to ciprofloxacin without direct exposure to the drug, and it achieved this using isolates cultured for just six hours—significantly less than the usual 24 hours required to culture a sample with antibiotics.

Although isolating the bacteria from a clinical sample, such as blood, urine, or stool, is still necessary, not having to expose the bacteria to ciprofloxacin can shorten the overall testing time from several days to just a few hours. While there are practical and economic constraints to this approach, it illustrates the potential of AI to significantly advance the battle against antimicrobial resistance. The researchers are now planning to expand their studies to include larger bacterial collections, aiming to refine their method to enhance speed and allow for the detection of resistance to ciprofloxacin and other antibiotics in various bacterial species.

“Given that this approach uses single cell resolution imaging, it isn’t yet a solution that could be readily deployed everywhere. But it shows real promise that by capturing just a few parameters about the shape and structure of the bacteria, it can give us enough information to predict drug resistance with relative ease,” said Dr. Sushmita Sridhar, who initiated this project while a PhD student in the Department of Medicine at the University of Cambridge. “What would be really important, particularly for a clinical context, would be to be able to take a complex sample – for example blood or urine or sputum – and identify susceptibility and resistance directly from that. That's a much more complicated problem and one that really hasn't been solved at all, even in clinical diagnostics in a hospital. If we could find a way of doing this, we could reduce the time taken to identify drug resistance and at a much lower cost. That could be truly transformative.”

Related Links:
University of Cambridge


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Electrolyte Analyzer
BKE-B
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.